Great Ormond Street Hospital

What Great Ormond Street Hospital does

Great Ormond Street Hospital (GOSH) is an NHS Foundation Trust and statutory public corporation founded in 1852, operating as one of the world's leading specialist paediatric tertiary centres in central London (Great Ormond Street, WC1N 3JH). The trust treats seriously ill children and young people, with approximately 750 patients seen per day and 212 active clinical trials underway, focused on the rarest and most complex childhood diseases across oncology, rare genetic conditions, treatment-resistant epilepsy, congenital heart disease, and esophageal atresia. Its core operating model combines direct clinical care with a translational research engine anchored at the Zayed Centre for Research into Rare Disease in Children and the NIHR GOSH Biomedical Research Centre, supplemented by the GOSH Learning Academy which delivered 18,605 learning opportunities annually. Differentiated capabilities include first-in-human delivery of base-edited CAR T-cell therapy (BE-CAR7, 82% deep remission and 64% disease-free survival), Luxturna gene therapy for Leber's congenital amaurosis, the world's largest international CAR T-cell immunotherapy trial for childhood solid tumors, and tissue-engineered lab-grown esophageal grafts capable of peristalsis.

The trust runs as a publicly funded entity, with revenue sourced from NHS tariff allocations, research grants (co-funding from Cancer Research UK, the National Cancer Institute, The Mark Foundation for Cancer Research, and others), and charitable donations via Great Ormond Street Hospital Charity. Private and international patients are also served through gosh.com.kw, an overseas private care channel. GOSH does not operate on a commercial SaaS or product-pricing model; its customer base is functionally segmented into NHS-referred paediatric patients with rare and complex conditions in the UK, paying international patients, and research participants enrolled in its clinical trial portfolio. The trust collaborates extensively with University College London on translational research, partners with US institutions including Dana-Farber Cancer Institute, Boston Children's Hospital, and Children's National Hospital on the NexTGen trial, and participates in the multi-funder C-Further childhood cancer consortium alongside Cancer Research Horizons and LifeArc.

Recent strategic activity includes the introduction of multiple new first-in-human therapies, the appointment of Karl Munslow Ong as Chief Executive and John Beswick as incoming Chief Financial Officer, the redevelopment of the Children's Cancer Centre, and an active GMC regulatory referral concerning a senior clinician involved as an expert witness in the Lucy Letby trial. GOSH holds a CQC "Good" rating (assessed July 2025) and Newsweek's World's Best Specialized Hospitals - Pediatrics 2025 designation.

Name

Great Ormond Street Hospital

Legal name

Great Ormond Street Hospital for Children NHS Foundation Trust

Website

https://gosh.nhs.uk

Company type

Public

Founded year

1852

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Great Ormond Street Hospital is a London-based NHS Foundation Trust founded in 1852, providing specialist paediatric care for rare and complex childhood diseases through 212 active clinical trials in gene therapy, CAR T-cell immunotherapy, and regenerative medicine.

Ownership category

akta.pro rank

Product category

Paediatric Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industry

Community & Regional General Hospitals (HLAFAAAB)

Keywords

• Paediatric healthcare services
• Rare disease treatment
• Clinical research trials
• Gene therapy research
• Medical education training

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Distribution channels2 records

Marketing channels4 records

Core offering

Great Ormond Street Hospital is a paediatric tertiary and quaternary care hospital providing specialised treatment for children with rare and complex diseases. Its core offerings combine direct clinical care (including gene therapy, CAR T-cell immunotherapy, and complex surgery) with a translational research portfolio of 212 active clinical trials and a professional education programme delivered through the GOSH Learning Academy. The hospital also offers fee-based international private patient services through gosh.com.kw.

Product overview

Great Ormond Street Hospital is a world-leading children's hospital offering specialized pediatric healthcare services. The hospital operates as a unified platform combining direct patient care with research and education. Key offerings include the Children's Cancer Centre (specialized oncology), Zayed Centre for Research into Rare Disease, NIHR GOSH Biomedical Research Centre, and 212 active clinical trials spanning gene therapies, CAR T-cell immunotherapy, and neurostimulation. The hospital also provides the MyGOSH patient app for digital access to services and operates the GOSH Learning Academy for professional education and training.

Differentiator

Problem solved

Functional benefit

Brands

• MyGOSH: Patient mobile application for hospital services and care management
• GOSH Learning Academy
• NIHR GOSH Biomedical Research Centre (BRC)

Products and services

• Paediatric Specialist Clinical Services
• International and Private Paediatric Care

Quantifiable outcome

• 91% reduction in seizures in children with Dravet syndrome
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Cancer Grand Challenges NexTGen TeamcoreStrategic or Co-development Partner · 8 April 2026International consortium leading the largest CAR T-cell immunotherapy trial for solid tumors in children and young people, with participants recruited across US and UK sites
• Children's National HospitalcoreStrategic or Co-development Partner · 8 April 2026US arm lead for CAR T-cell immunotherapy trial for solid tumors alongside Dana-Farber Cancer Institute and Boston Children's Hospital
• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 8 April 2026US arm lead for international CAR T-cell immunotherapy trial for childhood solid tumors
• Boston Children's HospitalcoreStrategic or Co-development Partner · 8 April 2026US arm co-lead for international CAR T-cell immunotherapy trial for solid tumors in young patients
• KU Leuven's Trellis Research GroupminorStrategic or Co-development Partner · 25 March 2026Academic partnership addressing gene therapy manufacturing costs through cost-effective AAV manufacturing infrastructure development
• C-Further ConsortiumcoreStrategic or Co-development Partner · 10 March 2026International consortium dedicated to childhood cancer therapeutics with initial $40 million budget; GOSH Charity is a core partner alongside Cancer Research Horizons and LifeArc
• Glycorex TransplantationcoreTechnology or Integration · 6 February 2026Glycosorb® ABO product routinely used since 2015 to facilitate ABO-incompatible transplantation at GOSH
• Premier InnminorGTM or Marketing Partner · 22 January 2026Charitable partnership where profits from Premier Inn's limited-edition sleepwear range featuring signature purple color go to Great Ormond Street Hospital Charity
• University College London (UCL)coreStrategic or Co-development Partner · 8 December 2025Research partnership for BE-CAR7 universal base-edited CAR T-cell therapy development, with GOSH Charity committing over £2m to widen access for additional patients
• UVA Comprehensive Cancer CenterminorStrategic or Co-development PartnerPartner for CF-012 Ewing sarcoma programme in C-Further consortium alongside Dana-Farber and Mass General Brigham
• MiNK TherapeuticsminorStrategic or Co-development PartnerPartner for CF-033 programme for multiple children's cancers including bone sarcoma, medulloblastoma, and AML in C-Further consortium
• University of SouthamptonminorStrategic or Co-development PartnerAcademic partner for CF-033 programme in C-Further consortium alongside MiNK Therapeutics

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Great Ormond Street Hospital for Children NHS Foundation Trust: Anchor entity (self-reference, retained for completeness).
• Texas Children's Hospital: Largest US children's hospital, part of Baylor College of Medicine, with major pediatric cancer, heart, and rare disease programs. Comparable in scale, scope of specialty services, and research output.
• Seattle Children's Hospital: Major US pediatric academic medical center with strong gene and cell therapy research programs, including CAR T-cell work. Comparable in scale, mission, and translational research focus.
• Dana-Farber Cancer Institute: US cancer institute co-leading the NexTGen CAR T trial with GOSH. Comparable as a research-intensive oncology partner with overlapping pediatric and translational cell therapy programs.
• Children's Hospital of Philadelphia (CHOP): US pediatric specialty hospital with globally leading cell and gene therapy programs (including the first FDA-approved personalized cell therapy for pediatric cancer). Comparable in research intensity, rare disease focus, and translational pipeline.
• Children's National Hospital: Washington DC pediatric specialty hospital and US lead for the NexTGen CAR T-cell solid tumor trial with GOSH. Directly comparable in pediatric oncology research depth and clinical trial infrastructure.
• Boston Children's Hospital: Largest pediatric research hospital in the US, co-leading the NexTGen CAR T-cell solid tumor trial with GOSH. Directly comparable as a quaternary pediatric specialty center with deep gene and cell therapy research programs.
• Hospital for Sick Children (SickKids): Toronto-based quaternary pediatric hospital and one of the world's largest pediatric research centers. Directly comparable as a specialty referral hospital with leading rare disease and genomics programs.
• Alder Hey Children's Hospital: UK pediatric NHS Foundation Trust and one of the largest children's hospitals in Europe. Comparable as a fellow NHS specialist pediatric provider serving as a regional quaternary referral center.

Regional players

• Royal Children's Hospital Melbourne: Australia's largest specialist pediatric hospital and a major pediatric research center (Murdoch Children's Research Institute). Comparable in pediatric specialty scope, but operates primarily in the Australian/Asia-Pacific market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/greatormondst
• YouTubeyoutube.com/user/GOSH1
• Facebookfacebook.com/GOSHospital
• LinkedInlinkedin.com/company/great-ormond-street-hospital
• Instagraminstagram.com/goshhospital
• TikToktiktok.com/@goshhospital

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Great Ormond Street Hospital